More recently, we have described upregulation of HDAC6 protein levels in CLL patients’ B cells and direct antitumor activity of selective HDAC6 inhibition in murine CLL (17). This evidence concerns the gene HDAC6 and B-cell chronic lymphocytic leukemia.